Physician profile
William B Solomon
NPI 1245225275
$46,451.24
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $11K · 2022: $1,200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29,300.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $3,568.44 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.43 | 2019 | |
| Exelixis INC. | $135.63 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.39 | 2019 | |
| Astellas Pharma US INC | $105.28 | 2019 | |
| Merck Sharp & Dohme LLC | $70.23 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $70.02 | 2019 | |
| Rigel Pharmaceuticals, INC. | $65.91 | 2019 | |
| Pfizer INC. | $65.68 | 2019 | |
| Lilly USA, LLC | $60.54 | 2019 | |
| Gilead Sciences, INC. | $49.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.33 | 2019 | |
| Emd Serono, INC. | $41.74 | 2019 | |
| Tersera Therapeutics LLC | $41.19 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $38.25 | 2019 | |
| Glaxosmithkline, LLC. | $29.16 | 2019 | |
| Tesaro, INC. | $28.00 | 2019 | |
| Janssen Biotech, INC. | $18.62 | 2019 | |
| Daiichi Sankyo INC. | $17.82 | 2019 | |
| Incyte Corporation | $16.01 | 2019 | |
| Genentech USA, INC. | $15.98 | 2019 | |
| Puma Biotechnology, INC. | $14.28 | 2019 | |
| Amgen INC. | $13.78 | 2019 | |
| Genzyme Corporation | $11.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.